Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI)

Analysts at Wolfe Research began coverage on shares of Palisade Bio (NASDAQ:PALI) in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The firm set an “outperform” rating and a $7.00 price target on the stock. Wolfe Research’s price objective suggests a potential upside of 284.62% from the stock’s current price.

A number of other equities research analysts have also weighed in on PALI. B. Riley Financial assumed coverage on shares of Palisade Bio in a report on Friday, January 9th. They set a “buy” rating and a $7.00 target price on the stock. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Stifel Nicolaus assumed coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Finally, HC Wainwright assumed coverage on shares of Palisade Bio in a report on Thursday, March 26th. They set a “buy” rating and a $7.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.20.

Palisade Bio Price Performance

PALI opened at $1.82 on Thursday. Palisade Bio has a fifty-two week low of $0.53 and a fifty-two week high of $2.64. The firm has a market capitalization of $301.90 million, a price-to-earnings ratio of -0.86 and a beta of 1.36. The company’s 50 day moving average price is $1.81 and its two-hundred day moving average price is $1.83.

Institutional Investors Weigh In On Palisade Bio

A number of institutional investors have recently modified their holdings of PALI. Cetera Investment Advisers bought a new stake in shares of Palisade Bio in the 4th quarter valued at $25,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Palisade Bio in the 4th quarter valued at $26,000. Virtu Financial LLC bought a new stake in shares of Palisade Bio in the 4th quarter valued at $28,000. Atom Investors LP bought a new stake in shares of Palisade Bio in the 4th quarter valued at $33,000. Finally, Barclays PLC bought a new stake in shares of Palisade Bio in the 4th quarter valued at $35,000. 11.79% of the stock is owned by institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.